Equities
Health CareHealth Care Providers
  • Price (USD)174.11
  • Today's Change2.12 / 1.23%
  • Shares traded4.27k
  • 1 Year change-25.64%
  • Beta1.1047
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data, and business consulting and is designed to meet the needs of its customers and the strategic business functions from research and development (R&D) through commercialization. Its four product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes, and partners across content management, training, quality management, assurance, and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. Veeva Data Cloud is a data platform comprised of connected reference data, deep data, and transaction data.

  • Revenue in USD (TTM)3.08bn
  • Net income in USD860.33m
  • Incorporated2007
  • Employees7.29k
  • Location
    Veeva Systems Inc4280 Hacienda DrivePLEASANTON 94588United StatesUSA
  • Phone+1 (925) 452-6500
  • Fax+1 (925) 452-6504
  • Websitehttps://www.veeva.com/medtech/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cooper Companies Inc4.09bn374.90m16.26bn15.00k44.291.9721.623.971.871.8720.4642.060.33121.715.29272,826.703.038.043.328.8665.5466.019.1624.661.136.320.23320.20495.0610.98-4.449.483.15--
Hologic Inc4.13bn543.80m16.75bn7.07k31.143.1919.964.062.412.4118.2823.510.46082.576.79583,663.406.0711.226.8212.8556.5160.2013.1821.993.3215.760.32460.001.741.66-28.35-12.69-0.5168--
Insulet Corp2.52bn246.20m17.08bn3.90k70.4312.3451.176.773.453.4534.8519.680.8331.626.02646,641.008.136.0010.057.0371.4667.059.769.222.1827.390.4230.0022.0722.92102.76104.84-4.75--
Illumina Inc4.34bn850.00m17.86bn8.60k21.326.5615.954.115.485.4827.8817.800.67092.615.34505,000.0013.13-10.1517.32-12.1566.6165.3919.57-23.181.7215.790.4221---0.66336.04169.505.32-4.77--
West Pharmaceutical Services Inc3.07bn493.70m18.04bn10.60k36.875.6827.725.876.796.7942.2844.110.77694.805.46--12.1115.2414.2918.1935.9137.8915.5918.672.34--0.069.996.257.440.2037.3610.395.51
Zimmer Biomet Holdings Inc8.23bn705.00m19.11bn17.00k27.201.5010.632.323.553.5541.4264.110.37031.105.17--3.173.033.583.4669.7171.018.569.101.104.740.371829.107.206.08-21.98--9.260.00
Steris PLC5.83bn708.66m24.36bn17.79k34.563.4120.354.187.197.1859.0972.930.56584.926.12327,662.406.915.047.595.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
DexCom Inc4.66bn836.30m26.95bn11.00k33.899.8124.775.782.072.0711.507.140.7273.024.20423,818.2013.048.8521.5812.5862.0963.9217.9414.211.59--0.3204--15.6019.3345.148.7512.81--
Veeva Systems Inc3.08bn860.33m28.62bn7.29k33.874.0631.809.295.145.1418.4142.840.4234--9.15422,472.4011.8311.3313.5014.3575.6772.6027.9323.96----0.000.0016.2019.9935.8418.8536.56--
Waters Corp3.17bn642.63m31.72bn7.60k30.0412.3837.3510.0210.7710.7753.0326.110.65692.464.05--13.3417.0314.5320.6859.2859.0120.3022.40--16.770.3546--6.996.000.75184.26-8.14--
Agilent Technologies Inc6.95bn1.30bn35.58bn18.10k27.565.2822.375.124.564.5624.3423.820.56553.294.94383,867.4010.6111.4412.8213.6752.7353.2518.7518.821.5218.300.332220.766.735.411.0912.6327.887.10
GE HealthCare Technologies Inc20.63bn2.09bn36.61bn54.00k17.653.5313.401.784.554.5545.0322.770.58935.934.31381,944.406.156.708.469.2539.9840.4410.4410.491.139.970.48661.854.843.744.570.755813.23--
Resmed Inc5.40bn1.49bn36.79bn10.60k24.965.8221.766.8210.1210.1236.7543.390.69012.345.53509,256.5019.0015.3321.9417.7660.8557.2927.5321.962.32--0.09528.949.8411.7237.2017.64-1.021.69
Data as of Feb 13 2026. Currency figures normalised to Veeva Systems Inc's reporting currency: US Dollar USD

Institutional shareholders

32.07%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202514.05m8.55%
BlackRock Fund Advisorsas of 31 Dec 20257.05m4.29%
AllianceBernstein LPas of 30 Sep 20255.94m3.62%
Fidelity Management & Research Co. LLCas of 30 Sep 20255.75m3.50%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20253.90m2.38%
Principal Global Investors LLCas of 31 Dec 20253.87m2.35%
SSgA Funds Management, Inc.as of 31 Dec 20253.59m2.18%
Geode Capital Management LLCas of 31 Dec 20253.17m1.93%
The Linonia Partnership LPas of 30 Sep 20252.97m1.81%
Tiger Global Management LLCas of 30 Sep 20252.42m1.47%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.